Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By microarray, Q-RT-PCR and 3'UTR luciferase assay, TAGLN, an early marker of smooth muscle differentiation and tumor suppressor, was identified as a target gene of miR-1587, thus providing a direct target to study miR-1587 functions.
|
30290263 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TAGLN is an actin-binding protein family that comprises three isoforms with theorized roles in smooth muscle differentiation, tumour development, lymphocyte activation, and brain chemistry.
|
29615809 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transgelin-1 (SM22α) has been recognized as a smooth muscle marker and a tumor suppressor, but many details of the working mechanisms remain unclear.
|
30301526 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although the role of transgelin in cancer is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.
|
26847345 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transgelin is supposed to be a tumor suppression gene and it is down-regulated in a variety of human cancers.
|
26242444 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We identified TAGLN as a downstream target of miR-144 and demonstrated that its expression is upregulated in osteosarcoma cell lines and tumor tissue and is inversely correlated with miR-144 expression.
|
25318625 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also overview the recent data on transgelin-2, a sequence homolog of transgelin, whose role in the tumor development might be contradictory to the role of transgelin.
|
24476357 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the interaction between cancer cells and the tumor microenvironment to determine how the fibroblasts from human gastric carcinoma facilitate tumorigenesis through TAGLN.
|
23510049 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Depletion of transgelin expression could suppress pancreatic tumorigenicity and tumor growth in vivo, and produce enhanced cytotoxic effects of gemcitabine on pancreatic cancer cells both in vitro and in vivo.
|
23331552 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we exchanged the constitutive promoter in the pEPI derivative pEPito by the tumor specific alpha fetoprotein (AFP) or the muscle specific smooth muscle 22 (SM22) promoter leading to specific transgene expression in AFP positive human hepatocellular carcinoma (HUH7) and in a SM22 positive cell line, respectively.
|
23734827 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reduction in SM22 levels would tend to promote cell survival when cells are under stress, such as in a hypoxic tumour environment, and may also contribute to increases in actin dynamics that favour metastatic potential.
|
22257561 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, SM22α overexpression enhances tumor cell growth and activates the IGF1R/PI3K/Akt pathway via direct interaction with IGF1Rβ.
|
22245152 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among them, transgelin, a 22 kDa protein also called SM22, was identified as a novel tumor suppressor protein, but little is known about this protein in tumors so far.
|
19329940 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent evidence suggests that transgelin acts as a tumour suppressor.
|
18378184 |
2009 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also studied possible genes downstream of RASSF1A in 16 primary non-small cell lung cancers and found that the expressions of SM22 and SPARC were significantly downregulated in RASSF1A-hypermethylated tumors.
|
15922865 |
2005 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In situ hybridization revealed that SM22-alpha is not expressed in the malignant cells but in mesenchymal cells of the tumor stroma.
|
11503213 |
2001 |